The parent company of a major monosodium glutamate producer listed on Bursa Malaysia's Main Market is moving to acquire full ownership of its subsidiary through a privatisation scheme that values the company at RM603.4 million. Ajinomoto Co Inc, which already controls just over half the shares in Ajinomoto (Malaysia) Bhd, has lodged a proposal with the board outlining a selective capital reduction and repayment process that would see all minority shareholders exit at RM20 per share, representing a substantial premium to recent trading prices.
The proposal addresses a longstanding concern among market observers: the near-absence of meaningful trading activity in Ajinomoto Malaysia shares over the past five years. Available data indicates that the company's average daily trading volume has languished at approximately 38,715 shares, rendering it exceptionally difficult for retail and institutional investors holding minority stakes to liquidate their positions without incurring significant market impact costs or extended holding periods. This structural liquidity problem has persisted despite the company's listing status, creating a disconnect between theoretical ownership rights and practical ability to realise value.
From the parent company's perspective, the privatisation unlock several operational benefits that have become increasingly attractive as global manufacturing strategies evolve. By removing the regulatory obligations associated with maintaining a public listing on Bursa Malaysia, Ajinomoto Malaysia can redirect management attention and financial resources away from compliance, disclosure reporting, and corporate governance requirements towards core business activities. The proposal explicitly cites the opportunity to simplify the corporate structure—a common motivation in Asian delisting scenarios where parent companies seek to consolidate regional operations under unified command structures.
Notably, Ajinomoto Malaysia has not accessed the capital markets for equity fundraising in over a decade, suggesting that public listing status no longer serves a functional purpose for corporate finance strategy. The company's issued share capital stands at RM65.1 million across 60.8 million shares, a relatively modest capitalisation that may struggle to attract meaningful institutional participation in a competitive regional investment environment. Removing the burden of public company obligations could allow management to pursue business strategies that might be constrained by quarterly reporting cycles or disclosure sensitivities.
The mechanics of the privatisation involve a creative capital restructuring that ensures sufficient cash reserves exist to compensate departing shareholders. The entitled shareholders—those holding the 49.62% stake not owned by Ajinomoto Co Inc—will receive RM603.4 million in total cash repayment, equivalent to RM20 per share held. To facilitate this distribution without depleting reserves excessively, the company plans a bonus share issue of 571.11 million new shares financed through capitalisation of retained earnings, adding RM571.1 million to the share capital base. Following this bonus issuance, all shares held by minority shareholders and their bonus allocation will be cancelled, leaving the parent company with complete 100% ownership.
The valuation reflects a meaningful premium across multiple benchmarks, positioning the offer as attractive to investors seeking exit opportunities. At RM20 per share, the price represents a 31.58% uplift from the closing price of RM15.20 recorded on June 19, 2026, the last trading day before the suspension announcement. When measured against the five-day volume-weighted average price, the premium reaches 30.68%, while comparison to the one-year volume-weighted average yields a 49.93% premium. This gradient of premiums across different time horizons suggests the company has priced the deal generously enough to overcome potential shareholder resistance while reflecting genuine value creation arguments.
For Malaysian and Southeast Asian investors, the delisting represents a microcosm of broader regional trends affecting smaller-cap companies on major stock exchanges. As capital markets across Asia become increasingly sophisticated and institutional, publicly-listed companies lacking sufficient scale, liquidity, or strategic rationale for public ownership face mounting pressures to either consolidate operations or withdraw from markets entirely. The low trading volume afflicting Ajinomoto Malaysia—itself a subsidiary of a major multinational corporation—illustrates how global rationalisation of equity structures can render local listings anachronistic despite operational competence.
The suspension of trading in Ajinomoto Malaysia shares commenced on June 22, 2026, with resumption scheduled for June 23. This brief suspension window provides administrative space for regulatory filings and shareholder notification processes required by Bursa Malaysia's listing rules. The proposed timeline, though compressed, allows affected shareholders minimal opportunity to deliberate or seek alternative valuations, reflecting the controlling shareholder's capacity to implement comprehensive restructuring once majority-equivalent support exists.
From a broader Malaysian business perspective, Ajinomoto's withdrawal from the public markets removes a long-established industrial company from the Main Market register. The monosodium glutamate industry, whilst economically significant to Malaysia's chemical and food ingredient manufacturing sectors, has never commanded substantial investor attention relative to technology, finance, or consumer sectors. The privatisation decision, therefore, represents a rational economic assessment that public listing costs outweigh strategic benefits for a commodity-oriented manufacturer with limited growth optionality and established, stable market position.
Minority shareholders must now decide whether to accept the RM20 per share offer or potentially challenge the valuation through merger and acquisition procedures prescribed by Malaysian regulatory authorities. The regulatory framework governing such transactions—typically administered through provisions of the Companies Act and Bursa Malaysia rules—permits minority shareholders to seek alternative valuations or oppose the scheme if they believe the consideration inadequately reflects intrinsic value. However, the substantial premium offered and the absence of recent trading comparables limiting upside arguments make successful opposition unlikely.
The privatisation exemplifies how controlling shareholders increasingly restructure Asian listed companies to optimise global operations. For Ajinomoto Co Inc, achieving full ownership of the Malaysian manufacturing subsidiary streamlines supply chain governance, allows unified regional pricing strategies, and eliminates the administrative friction of managing a separately-listed entity. These benefits, compounded by the minimal capital market utility the listing provides, create compelling arguments for delisting that ultimately favour the parent company's consolidated efficiency objectives over the theoretical benefits of maintaining a publicly-tradeable security.
